n-3 Fatty acids and their role in nephrologic practice

Curr Opin Nephrol Hypertens. 2001 Sep;10(5):639-42. doi: 10.1097/00041552-200109000-00014.


During the past year, a newly reported clinical trial has strengthened the argument for recommending daily treatment with n-3 polyunsaturated fatty acids in patients with immunoglobulin A nephropathy (the most common form of primary glomerulonephritis in the world) who are at high risk for progression of renal disease. Studies are underway that involve a combination of cyclosporine A, a commonly prescribed immunosuppressive agent in solid-organ transplantation, with a high-potency n-3 polyunsaturated fatty acid to reduce cyclosporine toxicity. Two studies reported during the past year show promise that dietary supplementation with n-3 polyunsaturated fatty acids will substantially decrease vascular access graft thrombosis in patients receiving maintenance hemodialysis, and may reduce hypercalciuria in patients who suffer from kidney stones.

Publication types

  • Review

MeSH terms

  • Catheters, Indwelling / adverse effects
  • Cyclosporine / adverse effects
  • Cyclosporine / therapeutic use
  • Drug Therapy, Combination
  • Fatty Acids, Omega-3 / therapeutic use*
  • Glomerulonephritis, IGA / drug therapy
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Nephrology / methods*
  • Professional Practice
  • Thrombosis / etiology
  • Thrombosis / prevention & control


  • Fatty Acids, Omega-3
  • Immunosuppressive Agents
  • Cyclosporine